These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 27124048)

  • 1. GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
    Lin WR; Chiang JM; Liang KH; Lim SN; Lai MW; Tsou YK; Hsieh TY; Hsu CK; Yeh CT
    Medicine (Baltimore); 2016 Apr; 95(17):e3487. PubMed ID: 27124048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.
    Domingo E; Kelly C; Hay J; Sansom O; Maka N; Oien K; Iveson T; Saunders M; Kerr R; Tomlinson I; Edwards J; Harkin A; Nowak M; Koelzer V; Easton A; Boukovinas I; Moustou E; Messaritakis I; Chondrozoumaki M; Karagianni M; Pagès F; Arnoux F; Lautard C; Lovera Y; Boquet I; Catteau A; Galon J; ; Souglakos I; Church DN
    J Clin Oncol; 2024 Jun; 42(18):2207-2218. PubMed ID: 38484206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer.
    McCleary NJ; Odejide O; Szymonifka J; Ryan D; Hezel A; Meyerhardt JA
    Clin Colorectal Cancer; 2013 Mar; 12(1):62-9. PubMed ID: 23102897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact of adjuvant chemotherapy duration on 3-year disease-free survival of colorectal carcinoma patients after radical resection].
    Qiu MZ; Teng KY; Ruan DY; Li YH; Chen XQ; Pan ZZ; He YJ; Wan DS; Xu RH
    Ai Zheng; 2009 Jul; 28(7):743-8. PubMed ID: 19624903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy.
    Huang CW; Ma CJ; Su WC; Chen YT; Tsai HL; Yeh YS; Chang TK; Hsu WH; Yu FJ; Wang JY
    Oncol Res; 2021 Sep; 28(7):701-714. PubMed ID: 32859280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An SNP Marker Predicts Colorectal Cancer Outcomes with 5-Fluorouracil-Based Adjuvant Chemotherapy Post-Resection.
    Chien H; Chu YD; Hsu YP; Yeh CT; Lai MW; Chang ML; Lim SN; Chen CW; Lin WR
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
    Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
    Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
    J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Values of applying white blood cell counts in the prognostic evaluation of resectable colorectal cancer.
    Wu J; Ge XX; Zhu W; Zhi Q; Xu MD; Duan W; Chen K; Gong FR; Tao M; Shou LM; Wu MY; Wang WJ
    Mol Med Rep; 2019 Mar; 19(3):2330-2340. PubMed ID: 30664202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
    Pectasides D; Karavasilis V; Papaxoinis G; Gourgioti G; Makatsoris T; Raptou G; Vrettou E; Sgouros J; Samantas E; Basdanis G; Papakostas P; Bafaloukos D; Kotoula V; Kalofonos HP; Scopa CD; Pentheroudakis G; Fountzilas G
    BMC Cancer; 2015 May; 15():384. PubMed ID: 25956750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.
    McCleary NJ; Meyerhardt JA; Green E; Yothers G; de Gramont A; Van Cutsem E; O'Connell M; Twelves CJ; Saltz LB; Haller DG; Sargent DJ
    J Clin Oncol; 2013 Jul; 31(20):2600-6. PubMed ID: 23733765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma.
    Yeh CT; Liang KH; Lin CC; Chang ML; Hsu CL; Hung CF
    Int J Cancer; 2014 Mar; 134(5):1214-24. PubMed ID: 23959947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
    Carrato A; Gallego-Plazas J; Guillén-Ponce C
    Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.
    Park JH; Kim NS; Park JY; Chae YS; Kim JG; Sohn SK; Moon JH; Kang BW; Ryoo HM; Bae SH; Choi GS; Jun SH
    J Cancer Res Clin Oncol; 2010 Aug; 136(8):1135-42. PubMed ID: 20091185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy.
    Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
    BMC Cancer; 2019 May; 19(1):421. PubMed ID: 31060539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
    Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
    Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
    Diao C; Cheng RC; Zhang JM; Wei XP; Su YJ; Liu QY; Xu JB
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):147-50. PubMed ID: 18646702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
    Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
    J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinations of single nucleotide polymorphisms WWOX-rs13338697, GALNT14-rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma.
    Lin WR; Hsu CW; Yeh CS; Chen YC; Chang ML; Liang KH; Lin CC; Chu YD; Yeh CT
    Asia Pac J Clin Oncol; 2018 Apr; 14(2):e54-e63. PubMed ID: 28695683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.